Search research articles
Contact Us
Filters
Showing results (91-100 of 97) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 97 results.
Journal of Medicinal Chemistry
|
March 23, 2016
Correction to Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators
Sébastien L Degorce, Andrew Bailey, Rowena Callis, et al.
Journal of Medicinal Chemistry
|
March 20, 2015
Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators
Sébastien L Degorce, Andrew Bailey, Rowena Callis, et al.
Journal of Medicinal Chemistry
|
January 18, 2012
Diverse heterocyclic scaffolds as allosteric inhibitors of AKT
Jason G Kettle, Simon Brown, Claire Crafter, et al.
Journal of Medicinal Chemistry
|
October 18, 2019
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88<sup>L265P</sup> Mutant Diffuse Large B Cell Lymphoma
Sébastien L Degorce, Rana Anjum, Andrew Bloecher, et al.
Journal of Medicinal Chemistry
|
January 15, 2019
Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists
James S Scott, Andrew Bailey, David Buttar, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 16, 2001
Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases
J G Conway, R C Andrews, B Beaudet, et al.
Journal of Medicinal Chemistry
|
November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell Lymphoma
James S Scott, Sébastien L Degorce, Rana Anjum, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 97) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 97 results.
Journal of Medicinal Chemistry
|
March 23, 2016
Correction to Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators
Sébastien L Degorce, Andrew Bailey, Rowena Callis, et al.
Journal of Medicinal Chemistry
|
March 20, 2015
Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators
Sébastien L Degorce, Andrew Bailey, Rowena Callis, et al.
Journal of Medicinal Chemistry
|
January 18, 2012
Diverse heterocyclic scaffolds as allosteric inhibitors of AKT
Jason G Kettle, Simon Brown, Claire Crafter, et al.
Journal of Medicinal Chemistry
|
October 18, 2019
Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88<sup>L265P</sup> Mutant Diffuse Large B Cell Lymphoma
Sébastien L Degorce, Rana Anjum, Andrew Bloecher, et al.
Journal of Medicinal Chemistry
|
January 15, 2019
Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists
James S Scott, Andrew Bailey, David Buttar, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 16, 2001
Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases
J G Conway, R C Andrews, B Beaudet, et al.
Journal of Medicinal Chemistry
|
November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell Lymphoma
James S Scott, Sébastien L Degorce, Rana Anjum, et al.
Page
of 10